The bacterial RNA polymerase holoenzyme consists of a catalytic core enzyme in complex with a σ factor that is required for promoter-specific transcription initiation. Primary, or housekeeping, σ factors are responsible for most of the gene expression that occurs during the exponential phase of growth. Primary σ factors share four regions of conserved sequence, regions 1-4, which have been further subdivided. Many primary σ factors also contain a nonconserved region (NCR) located between subregions 1.2 and 2.1, which can vary widely in length. Interactions between the NCR of the primary σ factor of Escherichia coli, σ
, and the β′ subunit of the E. coli core enzyme have been shown to influence gene expression, suggesting that the NCR of primary σ factors represents a potential target for transcription regulation. Here, we report the identification and characterization of a previously undocumented Chlamydia trachomatis transcription factor, designated GrgA (general regulator of genes A). We demonstrate in vitro that GrgA is a DNA-binding protein that can stimulate transcription from a range of σ 66 -dependent promoters. We further show that GrgA activates transcription by contacting the NCR of the primary σ factor of C. trachomatis, σ 66 . Our findings suggest GrgA serves as an important regulator of σ 66 -dependent transcription in C. trachomatis. Furthermore, because GrgA is present only in chlamydiae, our findings highlight how nonconserved regions of the bacterial RNA polymerase can be targets of regulatory factors that are unique to particular organisms. C hlamydiae are obligate intracellular bacterial parasites, and their hosts range from single cellular eukaryotes to humans (1) . In humans, Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen (2) . C. trachomatis is known for its ability to efficiently ascend from the lower genital tract to the upper genital tract, where chlamydial replication can have many devastating consequences, including infertility and pelvic inflammatory disease in women. In addition, some C. trachomatis serovars cause eye infection, which is still a major cause of blindness in underdeveloped countries (2) .
Chlamydiae have a unique developmental cycle with two alternating cellular forms. The metabolically inactive, infectious elementary body (EB) enters a vacuole through host cell endocytosis (3) . Inside the vacuole (termed inclusion), the EB develops into the proliferating but noninfectious reticulate body (RB). As RBs accumulate, they reorganize, in an asynchronous manner, back to EBs, which exit the host cell at the end of the developmental cycle (4) . Whereas a typical developmental cycle ranges from 2 to 4 d, the infection may enter a latent state, which is characterized by accumulation of aberrant reticulate bodies and a lack of EB production (5).
The C. trachomatis genome is ∼1 Mb in size and encodes ∼1,000 genes (6, 7) . Genome-wide microarray analyses have revealed that ∼80% of all genes are expressed a few hours after infection through the remaining developmental cycle. For the remaining genes, some are expressed immediately after chlamydial entry into the cell, and others are not transcribed until a middle or late stage. (8, 9) . Furthermore, certain gene transcripts exhibit increases or decreases in abundance as chlamydiae enter latency (10) . These observations suggest that alterations in gene expression manifest at the level of transcription contribute to the development of latency. Nevertheless, due to the limited number of genetic tools available in chlamydiae, only a few transcription regulators have been identified.
Here we describe the identification and characterization of a previously undocumented transcription factor that we call GrgA (general regulator of genes A). GrgA was identified based upon its ability to activate transcription in vitro from the promoter that controls the expression of defA, which encodes the peptide deformylase (PDF). We demonstrate that efficient transcription activation of the defA promoter by GrgA in vitro requires contact with both DNA and a portion of a nonconserved region (NCR) of the primary σ factor of C. trachomatis, σ
66
. We further show that GrgA can stimulate σ
-dependent transcription in vitro of three other genes that are expressed in vivo during different stages of the chlamydial developmental cycle. Our findings suggest that GrgA is not only a regulator of defA expression in vivo, but also a general transcription activator of many σ 66 -dependent genes. Furthermore, because GrgA is present only in chlamydiae, our findings highlight how regulatory factors that are unique to particular organisms can target nonconserved regions of the bacterial RNA polymerase (RNAP).
Results
Identification of GrgA as a defA Promoter-Binding Protein with Transcription Activation Activity. PDF catalyzes the removal of the N-formyl group from the leading methionine of newly synthesized proteins. Most bacterial proteins require the deformylation and subsequent removal of the N-terminal methionine to function properly. Furthermore, even for the small proportion of proteins that can function while carrying the N-formyl methionine, deformylation is necessary for the initiation of regulated degradation (11) . Thus, PDF is a potential therapeutic and/or prophylactic target for infectious diseases. Accordingly, small inhibitors of PDF have shown effectiveness against a variety of pathogens, including chlamydiae both in vitro and in vivo (12, 13) .
Our goal was to identify additional chlamydial proteins that might serve as potential therapeutic targets. Given that small molecules targeting PDF inhibit chlamydial growth, we sought to identify factors involved in the expression of defA, which might themselves serve as potential targets. To accomplish this goal, we used a DNA pull-down assay to identify chlamydial proteins that bound to a DNA fragment containing the defA promoter. To do this, we mixed cell extracts isolated from C. trachomatis-infected mouse L cells with streptavidin beads attached to either a biotinylated DNA fragment that carried sequences extending from position -144 to +52 of the defA promoter (pdf long ) or a biotinylated DNA fragment that carried sequences from position -54 to +52 (pdf short ). We then analyzed proteins associated with either the beads bound to the pdf long fragment or the beads bound to the pdf short fragment by liquid chromatography (LC)-MS/MS. From this analysis we identified C. trachomatis proteins with no previously assigned function that were enriched when the pull-down assay was performed with the pdf long fragment compared with the pdf short fragment.
We focused our attention on the Chlamydia-specific hypothetical protein that showed the highest enrichment in binding the pdf long fragment compared with the pdf short . This protein was encoded by an ORF designated CTL0766 in the genome of C. trachomatis L2. BLAST analysis did not detect significant homology between the CTL0766 protein and any nonchlamydial proteins, and no bacterial protein motif was identified in a motif search. We expressed and purified a His-tagged derivative of CTL0766 in Escherichia coli (Table S1 and Fig. S1 A and B) and tested its potential role in the regulation of defA gene transcription using an in vitro transcription assay (14) (Fig. 1 and Fig.  S2 ). Addition of CTL0766 stimulated transcription of the defA promoter by chlamydial RNA polymerase (cRNAP) in a dosedependent manner from the wild-type promoter (Fig. 1A) as well as two mutant derivatives (Z100 and GR10) (14) , which contain single base-pair substitutions that increase basal transcription ( Fig. 1 B and C and Fig. S2 ). These results demonstrate that the gene product of CTL0766 can activate transcription of the defA gene in vitro. As shown below, CTL0766 also acts as an activator of three other chlamydial genes tested. Accordingly, we rename the C. trachomatis gene CTL0766 grgA (general regulator of genes A).
GrgA Binds to DNA in a Sequence-Nonspecific Manner. To characterize the nature of the interaction between GrgA and the defA promoter, we first performed an EMSA using purified GrgA and a 32 P-labeled promoter fragment extending from position -144 to +52 of the defA promoter. Surprisingly, initial experiments detected no clear shifted band (Fig. S3A) , even though the same sequence of the defA promoter was used for initial pull-down experiment that led to the identification of GrgA (see above). We reasoned that the inclusion of poly(deoxyinosinic-deoxycytidylic) acid [poly(dI-dC)] in the reaction might have prevented GrgA from binding the defA promoter fragment. Consistent with this hypothesis, dose-dependent retardation of the defA promoter fragment by GrgA was readily detectable in the absence of poly (dI-dC) ( Fig. 2A) . However, GrgA-bound DNA did not migrate as a clear band in the resolving gel. At lower concentrations (0.2 and 0.3 μM) of GrgA the DNA appeared as smear in the gel, whereas at higher concentrations of GrgA (≥0.6 μM) the protein-DNA complex largely or completely remained in the loading well ( Fig.  2A) . We further performed GrgA pull-down assays to determine what effect shortening the DNA fragment carrying the defA promoter had on the binding of GrgA. Accordingly, we generated biotinylated defA promoter fragments of different lengths (Fig.  2B ) that were immobilized to streptavidin-conjugated agarose beads and determined the amount of GrgA that precipitated with equimolar amounts of each DNA fragment. Progressive removal from the 5′-end of the promoter resulted in a steady decrease in the amount of GrgA that was precipitated ( Fig. 2 C and D) , revealing a clear correlation between the length of the promoter DNA fragment and the amount of precipitated GrgA. These findings, which are consistent with the enrichment of GrgA association with the pdf long fragment compared with the pdf short fragment as detected by MS (see above), suggest that GrgA does not bind preferentially to defA promoter sequences, but rather binds DNA in a sequence-nonspecific manner. Consistent with this hypothesis, replacement of the sequences extending from -144 to +5 of the defA promoter fragment with unrelated DNA sequence had no effect on the amount of GrgA precipitated ( Fig. S3  B and C) . Furthermore, we found that GrgA could bind to DNA located in the 5′-untranslated region of the defA gene and to two fragments containing portions of the GrgA ORF (Fig. S3 D and  E) . Taken together, data presented in Fig. 2 and Fig. S3 indicate that GrgA binds DNA in a sequence-nonspecific manner.
GrgA-Dependent Transcription Activation Requires DNA Binding. We next pursued the identification of amino acid residues in GrgA that were required for sequence-nonspecific DNA binding. We constructed a series of GrgA mutants with deletions of 50-82 amino acids (Table S1 and Fig. S4 A and B) and assessed these mutants' abilities to associate with defA promoter DNA using both a pull-down assay (Fig. S4C ) and an EMSA assay (Fig. 3A) . GrgA mutants lacking amino acids 1-64 (Δ1-64), 65-113 (Δ65-113), 166-206 (Δ166-206), or 207-288 (Δ207-288) all exhibited DNA binding activities that were identical to that of the wildtype GrgA protein. In contrast, the GrgA mutant lacking amino acid residues 114-165 (Δ114-165) was severely compromised in its ability to bind DNA (Fig. 3A and Fig. S4C ), suggesting that residues 114-165 comprise a portion of GrgA that is essential for sequence-nonspecific DNA binding. Noticeably, this region is rich in positively charged lysine and arginine residues (Fig. S4D) , which may mediate the binding of GrgA to the negatively charged DNA. Furthermore, the lysine/arginine-rich sequence and a following region appeared to form a helix-turn-helix (Fig.  S4D) , a structural motif characteristic of DNA binding proteins.
We next assessed the effects of the various deletions in GrgA on the ability of GrgA to activate transcription from the defA promoter. Transcription activation was essentially that of the wild-type GrgA for the Δ65-113, Δ166-206, and Δ207-288 mutants. In contrast, the Δ114-165 mutant, which could not bind DNA, suffered a significant (∼75%) loss of transcription activation activity compared with wild-type GrgA (Fig. 3B) , suggesting that the ability of GrgA to bind DNA is important for GrgA-dependent transcription activation. In addition, the Δ1-64 mutant, which retained a strong DNA binding activity (Fig. 3A and Fig. S4C ), also displayed a significant (∼65%) loss of transcription activation activity (Fig. 3B) . These results indicate that Fig. 1 . GrgA stimulates transcription of the defA promoter in vitro. Shown are in vitro transcription assays performed using cRNAP, a DNA template carrying the indicated defA promoter variant, and the indicated concentration of NH·GrgA. The Z100 promoter derivative (used in B) carries a base pair substitution in the promoter -35 element, whereas the GR10 derivative (used in C) carries a substitution in DNA upstream of the -35 element (14) . Graphs show the averages and SDs for three independent measurements. We note that C-terminally His-tagged GrgA also demonstrated a dose-dependent stimulatory effect on defA promoter activity (Fig. S2 ). Single and double asterisks denote that the difference between control and GrgA-containing reactions were statistically significant (P < 0.05 and P < 0.01, respectively).
DNA binding is necessary but not sufficient for GrgA to efficiently activate transcription.
GrgA-Dependent Transcription Activation Requires Interaction with the Nonconserved Region of σ
66
. We have previously demonstrated that a hybrid RNAP holoenzyme consisting of the E. coli RNAP core enzyme and chlamydial σ 66 can transcribe from the defA promoter (14) . We therefore tested whether or not GrgA could activate transcription of the defA promoter in reactions performed using this hybrid holoenzyme. We found that addition of GrgA to transcription reactions performed using the hybrid holoenzyme stimulated transcription (Fig. S5A ) in a manner similar to the stimulatory effect observed in reactions performed using cRNAP ( Fig. 1 and Fig. S2 ). In contrast, GrgA was unable to activate transcription in reactions performed with E. coli RNAP core enzyme reconstituted with E. coli σ 70 (Fig. S5B ) or C. trachomatis σ
28
( Fig. S5C ). These findings raised the possibility that GrgA may stimulate transcription through direct interaction with σ
66
. Consistent with this hypothesis, Strep-Tactin-immobilized, C-terminally Strep-tagged σ 66 (CS·σ
) was able to precipitate GrgA ( We next used the GrgA mutants constructed for mapping the DNA binding region (Fig. S4A ) to determine what residues of GrgA were required for the interaction with σ 66 . The Δ65-113, Δ114-165, Δ166-206, and Δ207-288 GrgA mutants all retained the ability to interact with σ 66 (Fig. 4C) . Importantly, the finding that the Δ114-165 mutant retained the ability to bind σ 66 indicates that this mutant is stable, providing further support that the reduction in transcription activation observed with this mutant (Fig. 3B ) is a consequence of its inability to bind DNA. In contrast to the other GrgA mutants, the Δ1-64 mutant, which could efficiently bind DNA ( Fig. 3A and Fig. S4C ), did not detectably interact with σ 66 (Fig. 4C ). This finding suggests that the inability of the Δ1-64 mutant to efficiently stimulate transcription from the defA promoter ( Fig. 3B ) is due to the inability of the mutant to contact σ 66 . To further explore the hypothesis that GrgA-dependent transcription activation requires contact with σ
, we sought to identify regions of σ 66 that were required for the interaction with GrgA. Primary σ factors share four regions of conserved sequence, regions 1-4 (15-18). Furthermore, many primary σ factors carry a NCR between regions 1 and 2 that can widely vary in sequence and length (15) (16) (17) . We therefore constructed individual C. trachomatis σ 66 fragments (Table S1 and region 1 (residues 1-146), region 2 (residues 303-408), region 3 (residues 386-490), region 4 (residues 473-571), or the NCR (residues 121-322), and attempted to express them in E. coli. All of the fragments except the one comprising region 3 were successfully expressed and purified (Fig. S6B ). We next determined whether or not we could precipitate these fragments with GrgA, and found that only the fragment encompassing the NCR could precipitate GrgA ( Fig. 5A ), suggesting that GrgA contacts the σ 66 NCR. To further define the residues of the NCR that were important for GrgA binding, we constructed a series of σ 66 mutants that each contained 40-52 amino acid deletions in the NCR (ΔNCR1, which lacked residues 132-183; ΔNCR2, which lacked residues 184-224; ΔNCR3, which lacked residues 224-268; and ΔNCR4, which lacked residues 269-316; Fig. S6 C and D). Among these mutants, only ΔNCR4 lost the ability to bind to GrgA (Fig. 5B) , indicating that residues 269-316 of the NCR of σ 66 are required for interaction with GrgA.
We next tested the effect of deleting residues 269-316 of σ 66 on the ability of GrgA to activate transcription of the defA promoter. To do this, we performed in vitro transcription assays using a hybrid RNAP holoenzyme consisting of the E. coli RNAP core enzyme and either wild-type or mutant σ
. Removal of residues 269-316 in σ 66 had no effect on basal transcription but severely reduced the ability of GrgA to stimulate transcription (Fig. 5C ). In contrast, removal of other NCR residues that did not affect the ability of GrgA to bind σ 66 did not significantly affect GrgAdependent activation (Fig. 5C) . Thus, disrupting the interaction between GrgA and the NCR of σ 66 by either removing residues 1-64 of GrgA or residues 269-316 of σ 66 severely impairs GrgA-dependent transcription activation (Figs. 3, 4 , and 5C). Taken together, these results establish that the interaction between GrgA and the NCR of σ 66 is required for efficient transcription activation by GrgA.
GrgA Is a General Activator of σ 66 -Dependent Genes in Vitro. Given that GrgA bound DNA in a sequence-nonspecific manner and could activate transcription from the defA promoter, we next determined if the transcription activation activity of GrgA was limited to the defA gene. Accordingly, we assessed the effects of GrgA in vitro on the activities of three additional σ 66 -dependent promoters that are active at different stages of growth: ribosomal RNA promotor P1 (rRNA P1; early), major outer membrane protein A (ompA; middle), and histone-like protein A (hctA; late) (8, 9, 19, 20) . GrgA demonstrated significant stimulatory effects on all of the three promoters (Fig. 6) . Furthermore, both the Δ1-64 GrgA mutant (that does not interact with σ 66 ) and the Δ114-165 GrgA mutant (that does not bind DNA) exhibited significantly reduced levels of activation at each promoter compared with that observed with wild-type GrgA (Fig. 6) 66 derivatives recovered after precipitation. ΔNCR1 lacks residues 132-183; ΔNCR2 lacks residues 184-223; ΔNCR3, lacks residues 224-268; and ΔNCR4 lacks residues 270-316 (Fig. S6 ). (C) In vitro transcription assays performed in the presence or absence of 1.8 μM wild-type GrgA using a hybrid holoenzyme consisting of E. coli core and the indicated σ 66 derivative. The DNA template used for these assays was the Z100 defA promoter variant. Graph shows the averages and SDs for three independent measurements.
GrgA-dependent activation observed in the context of the rRNA P1, ompA, and hctA promoters, like that observed in the context of the defA promoter, requires GrgA to contact the DNA and the NCR of σ 66 .
Discussion
Here we identify a transcription factor from C. trachomatis, GrgA, which activates transcription of several σ 66 -dependent promoters in vitro by binding DNA and contacting the σ 66 NCR. These findings strongly suggest GrgA serves as an important regulator of σ 66 -dependent transcription in C. trachomatis.
GrgA Is a General Regulator of σ 66 -Dependent Transcription. Chlamydia is an important pathogen that has a unique developmental cycle with two alternating cellular forms. Knowledge of the extent to which the regulation of transcription contributes to the chlamydial life cycle has been limited, in part, by the lack of suitable experimental tools. In this regard, only a handful of transcription inhibitors (21) (22) (23) (24) (25) and three transcription activators (26) (27) (28) had been identified in chlamydiae before our study.
Our work identifies GrgA as a previously undocumented transcription factor in C. trachomatis. Although we originally identified GrgA on the basis of its ability to stimulate transcription from the σ 66 -dependent defA promoter (Fig. 1) , we found that GrgA stimulates transcription from several σ 66 -dependent promoters that are active at different stages of the chlamydial developmental cycle (Fig. 6 ). Based upon these in vitro findings, we propose that GrgA functions as a general transcription activator in C. trachomatis that up-regulates the expression of a broad spectrum of genes during all developmental phases. Consistent with this proposal, Western blot analysis indicates that GrgA is present in both chlamydial cellular forms, the EB and RB (Fig. S7) . Nevertheless, although our in vitro data provide strong evidence that GrgA functions in vivo as an important regulator of σ 66 -dependent gene expression, a direct test of the functional role that GrgA plays in vivo awaits the development of methods to perform targeted mutagenesis in Chlamydia.
GrgA-Dependent Transcription Activation Requires Contact with both DNA and the σ 66 NCR. We found that efficient GrgA-dependent activation requires GrgA to retain the ability to contact both DNA and the σ 66 NCR. In particular, we found that a GrgA mutant lacking amino acid residues required for DNA binding (Δ114- (Figs. 3, 4, and 6 ). The importance of the GrgA-σ 66 NCR interaction is further indicated by the inability of wild-type GrgA to efficiently activate transcription when reactions were performed with RNAP reconstituted with a σ 66 mutant lacking amino acids required for the interaction with GrgA (Fig. 5) .
Many Fig. S5) . Furthermore, the NCR of σ 66 and the NCR of σ 70 lack significant sequence similarity, suggesting that the NCR of σ 66 is unlikely to interact with the β′ subunit of the E. coli core enzyme. Thus, we consider it unlikely that GrgA activates transcription by influencing interactions between the σ 66 NCR and the RNAP core enzyme. We propose instead that GrgA activates transcription by stabilizing the binding of RNAP to promoter DNA. Nevertheless, defining the precise mechanism by which GrgA activates transcription awaits further investigation.
In conclusion, we have identified GrgA as a Chlamydia-specific transcription activator that exerts its stimulatory effect through interactions with the NCR of σ 66 and sequence-nonspecific interactions with DNA. Furthermore, because GrgA can stimulate transcription in vitro from several promoters that control the expression of genes that are critical for chlamydial growth, GrgA likely represents a promising antichlamydial target.
Materials and Methods
Purification and Identification of PDF Promoter-Binding Proteins. RBs were partially purified from 12 L of suspension culture and disrupted by sonication. The lysate was clarified by centrifugation. The clarified RB lysate was mixed with biotinylated PDF promoter DNA immobilized to streptavidin-conjugated agarose beads, which were then packed into a column and washed with buffer I (SI Materials and Methods) supplemented with 200 mM NaCl. Bound proteins were eluted using buffer I containing 600 mM NaCl. Proteins were mixed with SDS/PAGE sample buffer, resolved by electrophoresis, and digested by trypsin. Tryptic peptides were identified by nanoLC-MS/MS as detailed in SI Materials and Methods.
Purification of Recombinant GrgA. For transcription assays and protein-protein interaction assays, N-or C-terminally His-tagged GrgA (Table S1 ) was purified from E. coli extracts prepared in guanidine hydrochloride. Denatured proteins were purified with metal TALON affinity resin and renatured as detailed in SI Materials and Methods. Strep-tagged GrgA or σ 66 were purified using Strep-Tactin beads following manufacturer's instruction.
In Vitro Transcription Assay. The ability of GrgA to regulate transcription from chlamydial promoters was determined using a previously reported in vitro transcription assay (14, 31) with modifications, as detailed in SI Materials and Methods.
GrgA-DNA Interaction. EMSA was performed with or without poly(dI-dC). Streptavidin-immobilized biotinylated DNA fragments were used to precipitate GrgA. Alternatively, antibody immobilized GrgA was used to precipitate DNA. Experimental conditions for each of these assays are provided in SI Materials and Methods. -RNAP) and E. coli RNAP core enzyme (eCore) was purchased from EPICENTRE. Polyclonal mouse anti-GrgA antibody was a generous gift from Guangming Zhong (University of Texas Health Sciences Center, San Antonio, TX). Mouse anti-His antibody and horseradishconjugated mouse anti-His antibody were purchased from SigmaAldrich and Clontech, respectively. The TEN buffer contained 40 mM Tris·HCl (pH 7.5), 1 mM EDTA, and 150 mM NaCl. Buffer I contained 10 mM Tris·HCl (pH 8.0), 10 mM MgCl 2 , 1 mM EDTA, 10 mM 2-mercaptoethanol, and 7.5% (vol/vol) glycerol. The RB lysis buffer contained 10 mM Tris·HCl (pH 8.0), 0.6 M NaCl, 10 mM MgCl 2 , 1 mM EDTA, 7.5% (vol/vol) glycerol, 0.1% (vol/vol) Nonidet P-40, 0.3 mM DTT, 1 mM AEBSF, 10 mg/mL pepstatin, and 150 mg/mL lysozyme; DTT, AESBF, pepstatin A, and lysosome were added just before use. The chlamydial RNAP (cRNAP) storage buffer contained 10 mM Tris·HCl (pH 8.0), 10 mM MgCl 2 , 0.1 mM EDTA, 0.1 mM DTT, 100 mM NaCl, and 30% (vol/vol) glycerol. The TNG buffer contained 25 mM Tris acetate (pH 8.0), 150 mM NaCl, and 10% (vol/vol) glycerol.
Strains and Culture Conditions. Chlamydia trachomatis serovar L2 (L2; strain 434/Bu) was purchased from ATCC. HeLa cells, grown as adherent cultures, were used for the preparation of elementary body (EB) stocks (1, 2) . For the preparation of cRNAP, and purification of PDF promoter-binding proteins, mouse L929 cell suspension cultures were infected with EBs at an inoculating dosage of 3 inclusion-forming units per cell (2, 3). E. coli ArcticExpress was purchased from Agilent and cultured with the LB media. Table S1 . For the construction of wild-type expression vectors, DNA fragments were amplified using PfuUltra, digested with one or two endorestriction enzymes, and ligated to properly prepared plasmids. Most deletion mutants with truncation at either one or both termini were constructed through a similar strategy, but some were made using the QuikChange sitedirected mutagenesis kit. Point mutations were constructed using the QuikChange kit.
Preparation of Biotinylated DNA. Biotinylated DNA fragments were produced by Taq polymerase using a nonbiotinylated 5′ primer and a biotinylated 3′ primer designated PDF-TF-R-(5′-biotin), which carried a biotin residue at the 5′ position. The PCR products were purified using Qiagen PCR purification columns.
Preparation of PDF Promoter-Bound Agarose Beads. The above-purified biotinylated DNA was diluted 1:5 in TEN buffer. Streptavidin-conjugated agarose beads were washed twice with TEN buffer and then mixed with biotinylated DNA on a nutator at 4°C. At 30 min later, beads were washed three times with TEN buffer to remove unbound DNA.
Preparation of Partially Purified Chlamydiae from Bulk Culture. At 22 h after inoculation, L2-infected L929 cells were collected by centrifugation at 2,500 × g for 10 min at 4°C. All subsequent steps were performed on ice or at 4°C. The pellet was resuspended in 8 mL of cold PBS (pH 7.4) per liter culture. Cells were disrupted using a Daigger GEX130 Ultrasonic processor. The cell suspension was subjected to three 10-s cycles of sonication with the energy intensity level set at 30%. The lysate was centrifuged at 1,000 × g for 10 min, and the supernatant was collected. The pellet was resuspended in another 8 mL PBS, and subjected to an additional round of sonication and centrifugation as described above. The two supernatants were combined and centrifuged at 18,000 × g for 15 min. The resulting pellet contained partially purified chlamydiae.
Purification of PDF Promoter-Binding Proteins. All procedures were performed on ice or at 4°C. Chlamydiae partially purified from 12 L of suspension culture were resuspended in 24 mL reticulate body (RB) lysis buffer, and disrupted by ten 10-s sonication at 45% energy intensity. The lysate was centrifuged at 14,000 × g for 30 min. The supernatant was further clarified by four additional rounds of 15-min centrifugation. The supernatant resulted from the final round of centrifugation was diluted with 3 vol of buffer I. One-half of the diluted lysate was mixed with PDF promoter DNA-coated beads, prepared as described above, on a nutator (Clay Adams). At 1 h later, the beads were packed into a column, which were then washed with 20 resin vol of buffer I supplemented with 200 mM NaCl. The bound proteins were eluted using 4 vol of buffer I containing 600 mM NaCl. The elution was concentrated to 20 μL using Amicon centrifugal filters with a cutoff size of 3 kDa (Millipore). As control, nonbiotinylated PDF promoter DNA generated using the 5′ primer, PDF P1-F, and 3′, PDF-TF-R were added to the other half of the lysate, which were then mixed with plain streptavidin beads prewashed with TEN buffer. The remaining procedures for handling mock pull-down were the same as real pull-down.
LC-MS/MS. The concentrated pull-down samples were mixed with SDS/PAGE sample buffer and run ∼1 cm into a Bis-Tris 10% polyacrylamide gel (Novex Biotech). The entire band was excised, and proteins in the gel were reduced, carboxymethylated, and digested with trypsin using standard protocols. Peptides were extracted, solubilized in 0.1% trifluoroacetic acid, and analyzed by nanoLC-MS/MS using rapid-separation LC (Dionex) interfaced with a LTQ Orbitrap Velos (ThermoFisher). Samples were loaded onto a self-packed 100-μm × 2-cm trap packed with Magic C18AQ, 5 μm, 200 Å (Michrom Bioresources Inc.) and washed with buffer A (0.2% formic acid) for 5 min with a flow rate of 10 μL/min. The trap was brought in-line with the analytical column (Magic C18AQ, 3 μm, 200 Å, 75 µm × 50 cm) and peptides fractionated at 300 nL/min with a 30-min linear gradient of 2-45% buffer B [0.08% formic acid, 80% (vol/vol) acetonitrile]. MS data were acquired using a data-dependent acquisition procedure with a cyclic series of a full scan acquired in Orbitrap with resolution of 60,000 followed by MS/MS scans (acquired in linear ion trap) of 20 most-intense ions with a repeat count of two and the dynamic exclusion duration of 60 s.
The LC-MS/MS data were searched against the TrEMBL L2 using a local version of the Global Proteome Machine (GPM USB; Beavis Informatics Ltd.) with carbamidoethyl on cysteine as fixed modification and oxidation of methionine and tryptophan as variable modifications using a 10-ppm precursor ion tolerance and a 0.4-Da fragment ion tolerance.
MALDI-TOF/TOF Mass Spectrometry. Protein sample was diluted with 10 vol of matrix solution [10 mg/mL sinapinic acid in 50% (vol/vol) acetylnitrole/0.1% trifluoric acid]. A total of 1 μL of the mix was loaded onto an Opti-TOF 384-well plate and air-dried. Spectra were acquired with a 4800 MALDI TOF/TOF analyzer (AB Sciex) using positive linear high-mass mode from 15 K to 100 K. Each spectrum reported was the average of spectra generated from 2,000 lacer shots. BSA was used as external calibration.
Preparation of cRNAP. cRNAP was prepared using a published protocol (4) with modifications. A typical cRNAP purification experiment starts with 4 L of suspension culture. Chlamydial organisms were partially purified as described above, resuspended in 8 mL of freshly prepared RB lysis buffer with the omission of NaCl, and disrupted by sonication. Cell debris was removed by centrifugation as described for the preparation of lysate for the purification of promoter-binding proteins. To the final supernatant was added one-ninth vol of buffer I containing 1.5 M NaCl, and then 4 mL of the heparin-conjugated agarose beads. Following 2 h of mixing, each milliliter of the beads was packed into a column and washed with 20 mL of buffer I containing 200 mM NaCl. cRNAP was eluted with buffer I containing 1.5 M NaCl and collected as 250-μL fractions. Corresponding fractions collected from different columns were combined and dialyzed overnight against the cRNAP storage buffer. Small aliquots were made and stored at −80°C. Typically, fraction 5 was used for experiments. Extracts. ArcticExpress E. coli cells expressing His-tagged proteins were resuspended and lysed in 6 M guanidine hydrochloride solution containing 50 mM Hepes (pH 7.4) and 300 mM NaCl.
After the removal of cell debris by centrifugation, the supernatant was incubated with TALON metal affinity resin on a nutator for 1 h at room temperature. Resin was washed five times with the guanidine hydrochloride solution, packed into a column, and eluted with 45 mM Hepes (pH 7.4) containing 270 mM NaCl and 150 mM imidazole. To refold GrgA, the elution was dialyzed first overnight against a solution containing 2 M urea, 25 mM Hepes (pH 7.4), 300 mM NaCl, 0.5 mM AEBSF, 1 mM reduced glutathione, and 10% (vol/vol) glycerol, and then for additional 4 h against 25 mM Hepes (pH 7.4) containing 300 mM NaCl and 10% (vol/vol) glycerol. The dialyzed GrgA was concentrated and exchanged to the TNG buffer before it was aliquoted and stored at −80°C . Refold of σ 70 and σ 28 was accomplished by following procedures described by Panaghie et al. (5) and Yu and Tan (6), respectively.
In Vitro Transcription Assay. The assay in a total volume of 30 μL contained 400 ng supercoiled plasmid DNA, 1 mM potassium acetate, 8.1 mM magnesium acetate, 50 mM Tris acetate (pH 8.0), 27 mM ammonium acetate, 1 mM DTT, 3.5% (wt/vol) polyethylene glycol (average molecular weight, 8,000), 330 μM ATP, 330 μM UTP, 1 μM CTP, 0.2 μM [α-32 P]CTP (3,000 Ci/mmol), 100 μM 3′-O-methyl-GTP, 36 units of RNasin, RNAP, and indicated amount of GrgA or GrgA mutant, purified by procedures involving denaturing and refolding as described above. For reactions using cRNAP, the amount of cRNAP was 3.0 μL/reaction. For reactions using eCore and σ
66
, their concentrations were 20 nM and 100 nM, respectively. When different amounts of GrgA were used, the amount of GrgA storage buffer (i.e., the TNG buffer) remained constant. All control reactions involving GrgA received equal volume of TNG buffer. The reaction was allowed to pursue at 37°C for 30 min and terminated by the addition of 70 μL of 2.86 M ammonium acetate containing 4 mg of glycogen. After ethanol precipitation, 32 P-labeled RNA was resolved by urea-polyacrylamide gel electrophoresis, and visualized on a phosphorimager, and the intensities of the 157 base transcript bands were determined by ImageQuant software. Relative amounts of transcript were presented with that of the control reaction set as 1 unit. Data shown in bar graphs represent averages ± SDs from three or more independent experiments. Pairwise, two-tailed Student t tests were used to compare data from groups. Single and double asterisks indicate P ≤ 0.05 and P ≤ 0.01, respectively.
EMSA. EMSA was performed following a standard protocol (7) . A 5′ primer designated PDF P1-F of the PDF promoter, was reacted with γ-[
32 P]ATP in the presence of the T4 polynucleotide kinase. The resulting 32 P-labeled primer was used in conjunction with an unlabeled 3′ primer designated PDF-TF-R to amplify a DNA fragment containing the PDF promoter. The PCR-amplified fragment was purified with a Qiagen column. The GrgA-DNA binding reaction contained, in a total volume of 10 μL, 10 nM promoter fragment, an indicated amount of NH·GrgA, 1 mM potassium acetate, 8.1 mM magnesium acetate, 50 mM Tris acetate (pH 8.0), 27 mM ammonium acetate, 1 mM DTT, and 3.5% (wt/vol) polyethylene glycol (average molecular weight, 8,000), with or without 0.5 μg poly(dI-dC). After mixing for 1 h at 4°C, the binding mixture was loaded onto 6% (wt/vol) nondenaturing polyacrylamide gel. Free and GrgA-bound DNA fragments were visualized on a Storm Phosphorimager (Molecular Dynamics).
DNA Pull-Down of GrgA. The 50-μL streptavidin-conjugated agarose beads were washed twice with buffer TEN and mixed with 40 pmol of a biotinylated DNA fragment on a nutator for 30 min at 4°C. Beads were washed three times with buffer TEN to remove unbound DNA, and twice with transcription buffer. A 5-μg native purified NH·GrgA (full-length or deletion mutant) was added to the beads. The mixtures were incubated on a nutator for 1 h at 4°C. After two washes with transcription buffer and three times with PBS containing 1% (vol/vol) Triton X-100 (PBST), GrgA was resolved by SDS/PAGE and detected by colloidal blue stain or Western blotting using HRP-conjugated anti-His.
GrgA Pull-Down of DNA. DNA fragments corresponding to different portions of the PDF gene were produced by PCR. Primers were removed by PCR purification columns (Qiagen). DNA were eluted with water and diluted in transcription buffer. A total of 2 μg NH·GrgA were incubated on a nutator with 0.5 μL mouse anti-His (Sigma) or 1.0 μL control normal mouse serum for 1 h at 4°C, and then with 20 μL of protein A/G agarose (Sigma) for 2 h at 4°C. The beads were washed four times with PBST, resuspended in the transcription buffer, and mixed with a DNA fragment (40 pmol) on a nutator for 2 h at 4°C. After four washes with PBST, the reaction was heated at 95°C for 5 min to dissociate DNA from GrgA. DNA was visualized after electrophoresis in a 1.5% (wt/vol) agarose gel containing ethidium bromide.
Preparation of Highly Purified EBs and RBs. HeLa cells were infected with L2. EBs and RBs were released from infected cells 36 h later by sonication. Host DNA and RNA were removed by incubating the lysates at 37°C for 30 min after the addition of DNase (final concentration: 10 μg/mL) and RNase (100 μg/mL). The lysates were layered over 8 mL of 35% (vol/vol) RenoCal and centrifuged at 43,000 × g for 60 min in an SW28 rotor (Beckman Coulter). The EBs and RBs in the pellet were further purified by centrifugation through a RenoCal gradient (13 mL of 40%, 8 mL of 44%, and 5 mL of 52%) at 43,000 × g for 90 min in an SW28 rotor (8) . (1) . Note that the predicted helix ranging from residues 139-158 is rich in positively charged lysine and arginine residues. 
eCore + 66 + µM GrgA eCore + 28 + µM GrgA Fig. S5 . Activation of PDF gene transcription by GrgA is σ 66 -dependent. In vitro transcription assays performed using a hybrid holoenzyme consisting of E. coli core RNAP reconstituted with C. trachomatis σ 66 (A), E. coli core RNAP reconstituted with E. coli σ 70 (B), or E. coli core RNAP reconstituted with C. trachomatis σ 28 (C). Reactions were done using a DNA template carrying the Z100 defA promoter variant (A and B, and C Left) or the hctB promoter (1) (C Right) in the presence of the indicated concentration of NH·GrgA. Graphs show the averages and SDs for three independent measurements. Same as pMT1125-WT except it contains a C→A UP element mutation (2) pMT1125-Z100 Same as pMT1125-WT except it contains a C→A −35 element mutation (2) pMT1125-rRNA-P1 pMT1125 with chlamydial rRNA P1 promoter leading the G-less cassette This study pMT1187 pMT1125 with ompA promoter leading the G-less cassette This study pET21c-σ66-ΔNCR For expression of CH·ΔNCR, σ66 lacking NCR (residues 132-316); derived from pET21c-σ66 This study pET21c-σ66-ΔNCR1
For expression of CH·ΔNCR1, σ66 lacking residues 132-183 within the NCR; derived from pET21c-σ66
This study pET21c-σ66-ΔNCR2 For expression of CH·ΔNCR1, σ66 lacking residues 184-223 within the NCR; derived from pET21c-σ66
This study pET21c-σ66-ΔNCR3 For expression of CH·ΔNCR3, σ66 lacking residues 224-268 within the NCR; derived from pET21c-σ66
This study pET21c-σ66-ΔNCR4 For expression of CH·ΔNCR4, σ66 lacking residues 269-316 within the NCR; derived from pET21c-σ66
This study pLHN12-N-His-σ
70
For expression of N-terminally His-tagged E. coli σ70 (5) pET28a-σ28
For expression of N-terminally His-tagged chlamydial σ28 This study
